Progranulin is a potential prognostic biomarker in advanced epithelial ovarian cancers
- 31 January 2011
- journal article
- Published by Elsevier BV in Gynecologic Oncology
- Vol. 120 (1), 5-10
- https://doi.org/10.1016/j.ygyno.2010.09.006
Abstract
No abstract availableKeywords
Funding Information
- National Cancer Institute
- National Cancer Institute
- National Institutes of Health
This publication has 39 references indexed in Scilit:
- Current state of biomarker development for clinical application in epithelial ovarian cancerGynecologic Oncology, 2010
- Secretory Leukocyte Protease Inhibitor Antagonizes Paclitaxel in Ovarian Cancer CellsClinical Cancer Research, 2010
- Assessing Lead Time of Selected Ovarian Cancer Biomarkers: A Nested Case–Control StudyJNCI Journal of the National Cancer Institute, 2010
- Ovarian Cancer: Markers of ResponseInternational Journal of Gynecologic Cancer, 2009
- Overexpression of protease inhibitor‐dead secretory leukocyte protease inhibitor causes more aggressive ovarian cancer in vitro and in vivoCancer Science, 2009
- Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levelsAnnals Of Oncology, 2008
- Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancerAnnals Of Oncology, 2007
- Change in CA 125 levels after the first cycle of induction chemotherapy is an independent predictor of epithelial ovarian tumour outcomeAnnals Of Oncology, 2007
- Carcinoma of the OvaryInternational Journal of Gynecology & Obstetrics, 2006
- A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian CancerNew England Journal of Medicine, 1983